Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BetterLife Pharma ( (TSE:BETR) ) has shared an update.
BetterLife Pharma has issued 600,000 common shares to a third-party corporate adviser as payment for services provided since October 2025, underscoring its reliance on equity-based compensation to preserve cash as it advances its drug pipeline. The company has also extended by one year the maturity dates of convertible debentures originally due in February and March 2026, a move that eases near-term balance-sheet pressure and gives additional runway to progress its neurological and antiviral programs before significant debt obligations come due.
The most recent analyst rating on (TSE:BETR) stock is a Hold with a C$0.09 price target. To see the full list of analyst forecasts on BetterLife Pharma stock, see the TSE:BETR Stock Forecast page.
Spark’s Take on BETR Stock
According to Spark, TipRanks’ AI Analyst, BETR is a Neutral.
The score is held back primarily by fragile financials (no revenue, ongoing losses, negative equity), partially offset by improving recent cash burn/loss trends. Technicals are the main positive with clear upward price momentum, while valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on BETR stock, click here.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing BETR-001, a non-hallucinogenic, non-controlled LSD derivative aimed at treating various neurological disorders. The drug candidate is currently in preclinical and IND-enabling studies, supported by a synthesis patent and pending composition and method-of-use patents that could provide intellectual property protection into the early 2040s, and the company also holds a separate antiviral candidate for which it is seeking strategic development options.
Average Trading Volume: 115,180
Technical Sentiment Signal: Sell
Current Market Cap: C$9.87M
For a thorough assessment of BETR stock, go to TipRanks’ Stock Analysis page.